AstraZeneca

Researchers at Johns Hopkins, Children’s Hospital of Philadelphia, University of Pittsburgh, and Weill Cornell Medicine identified a novel cause of cytokine storm in COVID-19, linked to immune genes in the nasal cavity activating the renin-angiotensin-aldosterone system (RAAS), published in the Proceedings of the National Academy of Sciences.

The global MEK inhibitors market, valued at $995.1M in 2023, is projected to reach $1.5B by 2030, driven by cancer prevalence, genomics discoveries, clinical trial expansions, diagnostic advancements, and regulatory incentives.

The global psoriasis drug market is valued at US$ 14.08 billion in 2024, projected to grow at a CAGR of 6.9% to US$ 27.57 billion by 2034. Factors like smoking, alcohol, and cold temperatures increase psoriasis risk, driving market growth, especially in cold climates like the U.S. Key players include Amgen, Eli Lilly, and Novartis, focusing on strategic partnerships and product innovations. Corticosteroids are widely used for psoriasis treatment, prompting increased production by manufacturers.

Qiagen plans to relocate QIAstat-Dx operations to a new site in Esplugues de Llobregat by 2026, expanding its capabilities in syndromic testing and precision medicine. The site will include R&D, manufacturing, and regulatory affairs, aiming to enhance diagnostic capabilities in infectious diseases and beyond. The facility will be LEED Platinum certified and support partnerships with Eli Lilly and AstraZeneca.

Digital twins, AI simulations mimicking human biological complexities, are revolutionizing healthcare by predicting treatment outcomes, streamlining clinical trials, and addressing data disparities. The global market for healthcare digital twins is projected to exceed $38 billion by 2032. Early adopters like Bayer and AstraZeneca use digital twins to enhance clinical decision-making and trial efficiency. Challenges include regulatory compliance, data quality, and the ethical implications of AI errors in healthcare.

The idiopathic pulmonary fibrosis market is projected to grow from $3.89 billion in 2023 to $5.24 billion in 2028 at a CAGR of 6.2%, driven by factors like an aging population, limited treatment options, and advancements in diagnostic techniques. Key trends include product innovation and the rise of targeted therapies.

Life sciences sector resilient despite challenges; significant investments in ADCs, CGTs, AI, and CDMOs. ADCs and CGTs driving growth, with China leading in clinical trials and innovation. AI transforming drug discovery and clinical trials. APAC region dominating clinical trials, especially in oncology. China's biopharma sector booming, attracting global investments. CDMOs adopting digital revolution and AI for agile manufacturing. BIOSECURE Act impacting Chinese biotech companies, benefiting Indian CDMOs.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

Amgen's MariTide, an experimental obesity treatment, showed a 20% weight loss in trials but common side effects like nausea and vomiting limit its competitiveness. Eli Lilly and Novo Nordisk's next-gen drugs, potentially achieving 25% weight loss, dominate the market. MariTide's antibody-linked peptide mechanism offers durability but faces Phase III trials. Amgen's stock fell 12.3% post-report, reflecting market skepticism.

Hutchmed renews contract with China's NHSA; Orpathys (savolitinib), an oral MET TKI for NSCLC with MET exon 14 skipping alterations, remains in the NRDL until Jan 1, 2025, under current terms. Orpathys, jointly developed by Hutchmed and AstraZeneca, is the first selective MET inhibitor in China and the NRDL.